U.S. Consumer Finance Stock News

Why Quest Diagnostics Is On Investors’ Radar Today Quest Diagnostics (DGX) is drawing attention after recent trading, with the share price closing at $174.44 and posting mixed short term returns, including a 1 day decline and modest moves over the past week. See our latest analysis for Quest Diagnostics. While the recent 1 day and 30 day share price returns have been negative, Quest Diagnostics’ 1 year total shareholder return of 17.09% and 5 year total shareholder return of 54.70% point to...

UBS coverage puts MBX Biosciences in focus MBX Biosciences (MBX) is back on investors’ radar after UBS initiated coverage with a rating, highlighting the company’s pipeline in metabolic and endocrine diseases and recent Phase II data. See our latest analysis for MBX Biosciences. That fresh UBS coverage lands at a time when MBX Biosciences’ share price has climbed to US$31.66, with a 90 day share price return of 118.34% and a 1 year total shareholder return of 131.26%. This suggests momentum...

Wolfe Research’s downgrade of XPO (XPO), tied to a cautious view on the less than truckload sector and leadership changes as Mario Harik becomes chairman, has drawn fresh investor attention to the stock. See our latest analysis for XPO. At a share price of $146.73, XPO’s recent 2.0% 1 day share price return and 14.25% 90 day share price return sit alongside a 9.35% 1 year total shareholder return and very large 3 year total shareholder return. This suggests momentum has been building even as...

RingCentral, Inc. has appointed Mahmoud ElAssir, Chief Technology Officer at UnitedHealth Group and a veteran AI and cloud infrastructure leader, to its Board of Directors effective January 7, 2026. His background in running AI-native, real-time customer engagement platforms at very large scale aligns closely with RingCentral’s focus on AI-powered communications and cloud modernization. We’ll now examine how adding an AI and cloud infrastructure expert to the Board could influence...

Ouster (OUST) has drawn fresh attention after announcing that CEO Angus Pacala, CFO Ken Gianella and SVP Chen Geng will present at the 28th Annual Needham Growth Conference on January 15, 2026. See our latest analysis for Ouster. That conference appearance comes after a strong 7 day share price return of 19.26% and a 30 day share price return of 14.88%, even though the 90 day share price return shows a 10.30% decline. At the same time, the 1 year total shareholder return of 146.20% and 3 year...

Analyst downgrade puts Ryder System (R) back in focus Wolfe Research recently cut its rating on Ryder System (R) from Outperform to Peer Perform while leaving its price target unchanged. This shift stands out against more supportive views from other firms. For you as an investor, this kind of mixed analyst backdrop can be a useful moment to pause, review the stock’s recent returns, and reassess how Ryder fits into your portfolio and risk tolerance. See our latest analysis for Ryder...

In early January 2026, CNH Industrial’s financing arm priced US$500 million of senior unsecured notes due 2031, while the group added new Chief Manufacturing and Chief Legal and Compliance Officers to its global leadership team. Alongside this funding move, CNH Industrial’s ag tech innovations earned three AE50 Awards, underlining its push into higher-value digital farming solutions. We’ll now examine how the US$500 million note issuance and ag tech awards may influence CNH Industrial’s...

What is moving Kymera Therapeutics stock today? Kymera Therapeutics (KYMR) is back in focus after reporting strong STAT6 degradation data from its BroADen trial for KT-621 in atopic dermatitis, alongside interest building ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference. See our latest analysis for Kymera Therapeutics. At a share price of $74.77, Kymera has had a mixed few months, with a 30 day share price return of a 16.63% decline, a 90 day share price return...

Marriott Vacations Worldwide recently reported that Executive Vice President John D. Fitzgerald bought additional company shares, raised its quarterly dividend to US$0.80 per share paid in early January 2026, and extended its share repurchase authorization through the end of 2026. Together, insider buying, a higher cash payout, and continued buyback capacity highlight management’s willingness to return capital to shareholders and signal confidence in the business. Next, we’ll examine how the...

Event context for Capital Southwest Capital Southwest (CSWC) has attracted fresh attention after recent share price moves, with the stock showing positive total returns over the past year and the past 3 months. This performance has prompted investors to reassess its current valuation. See our latest analysis for Capital Southwest. The recent 14.1% 90 day share price return, alongside a 1 year total shareholder return of 18.56%, suggests momentum has been building around Capital Southwest at a...

Pomerantz LLP has begun investigating RH on behalf of investors after the company reported fiscal year 2024 earnings and revenue that fell short of its earlier guidance, prompting questions about possible securities law violations or other unlawful practices by certain officers and directors. This legal scrutiny adds a new layer of business and governance risk for RH, coming immediately after already disappointing operational results. We’ll now examine how the securities fraud investigation...

VICI Properties, an S&P 500 experiential REIT owning 93 gaming, hospitality and entertainment assets, has drawn fresh attention after past share price softness, with recent commentary emphasizing its diversified Las Vegas and regional casino portfolio, long-term triple-net leases and disciplined acquisition approach. Analysts and researchers highlight that VICI’s inflation-linked leases, focus on sale-leaseback and development funding deals, and multi-year history of dividend growth underpin...

Event context for Universal Technical Institute (UTI) Universal Technical Institute (UTI) shares recently closed at $27.50, with performance showing a 10.7% gain over the past week and month, but a 9.4% decline across the past 3 months. See our latest analysis for Universal Technical Institute. While the share price has eased back 1.7% over the last trading day, the 7 day and year to date share price returns of 10.7% sit alongside a very large 3 year total shareholder return. This suggests...

Willis Lease Finance (WLFC) has drawn fresh investor attention after launching Willis Aviation Capital, a new division that manages third-party aviation assets and capital through discretionary funds, in partnership with Blackstone Credit & Insurance and Liberty Mutual Investments. See our latest analysis for Willis Lease Finance. The WAC launch and new partnerships appear to coincide with a sharp shift in sentiment, with a 90 day share price return of 18.77% and a five year total shareholder...

Reliance (NYSE:RS) is back in focus as investors track headlines around the company’s crude oil sourcing, including speculation over Venezuelan and Russian supplies, while they also watch for its upcoming quarterly results. See our latest analysis for Reliance. Recent headlines around Venezuelan and Russian crude have arrived alongside a $308.83 share price and solid momentum, with a 90-day share price return of 12.12% and a 5-year total shareholder return of 162.73%, suggesting sentiment has...

What Kilroy Realty’s Latest Metrics Tell Investors Kilroy Realty (KRC) is back on many watchlists after recent trading left the stock around $39.85, with an intrinsic discount of about 23% and a value score of 5 catching investor attention. See our latest analysis for Kilroy Realty. Recent trading has been mixed, with a 7 day share price return of 4.81% but a 30 day share price return decline of 1.51%, while the 1 year total shareholder return of 18.94% suggests longer term holders have seen...

La-Z-Boy (LZB) has been drawing attention after recent share price moves, with the stock closing at $39.58 and showing mixed returns over the past year, month, and past three months. See our latest analysis for La-Z-Boy. The recent 1-day share price return of 1.44% and 7-day share price return of 6.11% come on top of a 23.19% 90-day share price return. At the same time, the 1-year total shareholder return is 6.79% lower and the 3-year total shareholder return is 58.90% higher. This suggests...

In early January 2026, Taylor Morrison Home drew fresh attention after Citizens initiated coverage with a positive Market Outperform rating and highlighted the builder’s exposure to resilient move-up and active adult buyers, while federal agencies moved to purchase US$200.00 billion in mortgage bonds to support homebuyers. Alongside new analyst support, Taylor Morrison’s decision to add experienced finance executive Amanda Whalen to its board signals a focus on strengthening governance and...

Earlier this month, Healthpeak Properties announced plans to launch an IPO for Janus Living, a new senior housing REIT that will receive 34 communities with 10,422 units, while Healthpeak retains a majority stake and intends to use proceeds for acquisitions, debt repayment, and general corporate purposes. This move effectively separates Healthpeak’s senior housing portfolio into a dedicated vehicle, potentially changing how investors assess the company’s growth profile, risk mix, and capital...

If you are wondering whether Synopsys is priced attractively right now, it helps to step back and look at both the recent share moves and what they might be implying about value. The stock closed at US$525.18 recently, with returns of 9.3% over the last week, 15.9% over the last month, 9.3% year to date, 6.6% over 1 year, 57.7% over 3 years and 102.8% over 5 years. This gives plenty of context for any thoughts you might have about growth potential or shifting risk perceptions. Recent...

Why recent automation gains and cost controls matter for C.H. Robinson Recent analyst commentary on C.H. Robinson Worldwide (CHRW) has focused on the company’s tighter cost controls and increased use of automation and artificial intelligence. These measures have helped offset softer revenue trends and supported better than expected earnings. With fourth quarter results expected at the end of January and a forecast for a single digit earnings decline, investors are watching whether these...

Aquestive Therapeutics recently disclosed that the FDA has identified unspecified deficiencies in the New Drug Application for its orally delivered epinephrine film Anaphylm, pausing labeling discussions and potentially affecting the timing of any approval decision ahead of the scheduled 31 January 2026 PDUFA date. At the same time, the company is pressing ahead with plans to seek approvals for Anaphylm in Canada, Europe, and the UK in 2026, signaling an effort to build a global,...

Apogee Enterprises (APOG) drew fresh attention after disappointing third quarter results, a reduced fiscal 2026 outlook, and the resignation of its Chief Financial Officer coincided with a sharp one day share price drop. See our latest analysis for Apogee Enterprises. The recent selloff came on top of already weak momentum, with a 30 day share price return showing an 11.6% decline and a 1 year total shareholder return showing a 28.7% decline. This suggests sentiment has been fading even...

In recent days, Waystar Holding has attracted fresh attention as Wells Fargo and RBC Capital both issued supportive research coverage highlighting the company’s cloud-based, AI-enabled healthcare payments platform. This cluster of positive analyst opinions underscores growing interest in Waystar’s role in healthcare payment digitization and the perceived strength of its integrated technology offering. With this backdrop of upbeat analyst coverage, we’ll now examine how such endorsement...